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Abstract. The outcomes of treatment of physical illnesses
are strongly affected by the presence of schizophrenia. We
aimed to quantify the clinical course of schizophrenic breast
cancer patients who were eligible for adjuvant chemotherapy
to determine whether patients with this mental illness receive
appropriate treatment for this physical illness. We searched
the national Department of Veterans Affairs (DVA) computer
database using computer codes for schizophrenia to identify
patients who later developed breast cancer and were treated
in DVA medical centers. Computer-based data were supplemented with chart-based clinical indicators. There were
55 subjects who appeared to be appropriate candidates for
adjuvant systemic therapy. A number of these candidates
were not offered postoperative endocrine or cytotoxic chemotherapy, while others refused treatment or were non-compliant.
Behaviors typical of schizophrenic subjects, including
hostility to caregivers, often disrupt their care. Schizophrenic
patients often have advanced-stage cancer at diagnosis, often
delay diagnosis and are frequently hostile towards healthcare
workers. Many of these patients refuse therapy and/or are
non‑compliant.
Introduction
Breast carcinoma is the most common type of cancer (with
the exception of non-melanoma skin cancer) and is the second
leading cause of cancer-related mortality in American women.
The incidence is approximately 123 per 100,000 women in
the United States. The age-adjusted mortality rate in the US
is approximately 24 per 100,000 women per year. The associ-
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ated lifetime risk for women is over 12%, and over 2.5 million
women currently living have a history of breast cancer in the
US (1). With advancements in treatment, the mortality rate has
declined over the last few decades.
There are various effective therapies available for breast
cancer, and breast-conserving treatment is common (2). The use
of adjuvant systemic chemotherapy for early-stage breast cancer
produces a 23% or greater increase in disease-free survival
duration and a 15% or greater increase in the overall lifetime
survival rate (3). This has led to an improved quality of life
with generally tolerable toxicities. Accumulating evidence
suggests that breast cancer is a heterogeneous disease (4).
The early diagnosis and optimal treatment of breast cancer
are essential (5). Delayed detection leads to poor outcomes
and may be due to patient factors (including late presentation or lack of appreciation of the significance of a breast
mass), physician factors (including misdiagnosis or delay
in consultation requests) and/or societal factors (including
inadequate access to care or insurance-related delays). All
of these affect patients with schizophrenia. Recent investigations have focused on the physical health status of individuals
with schizophrenia. Breast cancer is probably more common
in schizophrenic patients than in the population as a whole.
In their study, Bushe et al recently reviewed this topic (6).
However, screening for common physical illnesses, such as
breast cancer, is substantially less among such individuals than
in the population as a whole.
Schizophrenia is a serious mental illness characterized by
psychotic symptoms. It is typically chronic and causes characteristic abnormalities in perception, speech, behavior and
thought. The diagnosis is based solely on clinical factors.
Criteria for the diagnosis have been codified and published
by the American Psychiatric Association (7) (Table I).
Schizophrenia is believed to be the most disabling of mental
disorders and places a large financial burden on patients,
families and society. The incidence is low (15.2 per 100,000
individuals per year), but lifetime prevalence is relatively high
(7.2 per 1,000) (8,9). Approximately 1% of all populations
worldwide studied thus far are afflicted. Since there are over
194,000 new patients diagnosed with breast carcinoma in the
US each year and because the prevalence of schizophrenia in
the US is more than 1% of the population, we estimate that
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Table I. Diagnostic criteria for schizophrenia.
Categories
Characteristic symptoms
Social/occupational dysfunction
Duration
Organic etiology exclusion
Schizoaffective and
mood disorder exclusion
Pervasive developmental
disorder relationship

Details/Explanation
Two or more symptoms during a one-month period: delusion, hallucinations,
disorganized speech, disorganized/catatonic behavior and negative symptoms
Marked decrease since onset of disturbance in work, relationships and self-care
Continuous signs for at least six months
Includes: substance abuse or general medical conditions (including brain lesions,
seizures and endocrinopathies)
Episodes of major depression, manic, or mixed episodes
Autism or other pervasive developmental disorders with characteristic symptoms of
schizophrenia for >1 month is sufficient for the diagnosis of schizophrenia

All criteria are taken from the Diagnostic and Statistical Manual of Mental Disorders (7).

1,000-2,000 people with schizophrenia are diagnosed with
breast cancer each year.
Providing medical care for unrelated physical disorders in schizophrenic patients presents unique challenges.
Outcomes such as interactions between the mental illnesses
and physical illnesses are of interest (10), but there are no
studies pertaining to outcomes in populations of individuals
with concurrent breast cancer and schizophrenia. Previously,
we reported our analysis of the experience of the Department
of Veterans Affairs (DVA) with the treatment of appendicitis
in patients with schizophrenia (11). In this study, we aimed
to describe the outcomes of management in a large population‑based sample of schizophrenic patients with breast
cancer in the DVA who were offered adjuvant chemotherapy.
Surgeons are usually dominant figures in breast cancer care.
We therefore suggest management strategies for such patients
based on this analysis.
Materials and methods
Materials. Approval for this study was obtained from the
institutional review board. The Patient Treatment File (PTF),
the national archiving system for inpatient data in the DVA
medical system, was accessed to retrieve data of interest.
The PTF was searched to identify patients with the
International Classification of Diseases, Ninth Revision, Clinical
Modifications (ICD-9-CM) diagnostic codes for schizophrenia
or schizoaffective disorder (codes 295.00‑295.85) who were also
diagnosed with breast cancer (codes 174-174.9, 198.2, 198.81,
217, 233.0 and 611.72) during the fiscal years 1999‑2005. The
PTF identified appropriate patients based on these computer
codes and yielded data concerning demographics, comorbid
diseases and procedures.
To supplement the PTF data, we requested chart‑based
information from the DVA medical centers where patients
had received their initial breast cancer treatment. These data
included discharge summaries, progress notes, operative
reports, medical oncology consultation summaries, psychiatry
consultation notes and pathology reports. To obtain further

information regarding the psychiatric history of each patient,
we requested medical records predating admission for breast
cancer; charts from the postoperative period were also
obtained. Patients were classified as having received some
type of mastectomy, lumpectomy or local excision as part of
a curative-intent strategy if the records revealed breast carcinoma (codes 174-174.9, 198.2, 198.81, 217, 233.0 and 611.72).
From this pool of patients we selected patients who appeared
to be suitable candidates for adjuvant chemotherapy, according
to the current National Comprehensive Cancer Network (12)
and St. Gallen consensus conference standards (13).
In total, 27 (49%) Caucasian, 19 (35%) African-American,
3 (5%) Hispanic and 6 (11%) patients of other ethnicities
were included in this study. There were 18 males (33%) and
37 females (67%). The mean age at the time of surgery was
53 years (standard deviation, 11 years). Of the 44 patients for
whom living conditions were documented, 24 (55%) were
no longer living independently (i.e., they were living in the
homes of family members, assisted living facilities, group
homes, mental institutions or nursing homes), 17 (39%) were
independent and 3 (7%) were homeless. Additionally, 10 of the
17 (59%) schizophrenic patients living independently at the
time of breast cancer diagnosis for whom data were available
had been institutionalized within two years prior to their breast
cancer treatment.
The majority of our patients (29/55 patients, 53%)
were diagnosed with paranoid schizophrenia (7) (Table I).
Other subtypes of schizophrenia included undifferentiated (9/55 patients, 16%), residual (2/55 patients, 4%) and
catatonic schizophrenia (1/55 patients, 2%). Patients with
schizoaffective disorder (15/155, 27%) were also included. Of
the 48 patients for whom the antipsychotic drug regimen was
specified, 13 were taking a typical antipsychotic agent (such as
thioridazine or haloperidol), 35 were taking an atypical antipsychotic agent (such as risperidone or clozapine), 5 were taking
both types of drugs and 3 were on no antipsychotic drugs. The
two most common outpatient medications administered were
olanzipine (an atypical agent used by 17/48 patients, 35%)
and risperidone (an atypical agent used by 12/48 patients,
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Table II. Patient behaviors characteristic of schizophrenia
observed in our subjects (n=55).

Unwarranted disruptive behavior
Unwarranted removal of intravenous
catheter by patient
Failure to follow activity restrictions
Requirement for restraints
Self-mutilation
Unwarranted refusal to eat
Other adverse behaviorsa

Table III. Evidence of disordered thought observed in our
subjects (n=55).

n

%

Symptoms

7
1

13
2

2
1
1
2
6

4
2
2
4
11

Confusion
Lack of insight
Auditory hallucinations
Visual hallucinations
Non-auditory/non-visual hallucinations
Delusions
Paranoia
Abnormal affect
Suspiciousness
Ideas of reference
Looseness of associations
Thought blockinga

Mention of the behavior in the medical record was accepted as
evidence that the behavior occurred and was significant enough in
the opinion of a caregiver to warrant mention. Lack of mention of
the behavior was taken as evidence that the behavior did not occur.
a
Attacking health care workers (with fists), throwing objects at health
care workers, confusion about instructions from physicians leading to
inability to appear for scheduled appointments.

25%). Of the 38 patients for whom documentation of ability to
provide an accurate history was available, 15 patients (39%)
were described by a physician in the record as having a poor or
questionable ability to provide a reliable history.
Methods and statistical analysis. We used simple descriptive
statistics to portray the demographic data, clinical course and
patient outcomes. Subjects were excluded from further review
according to prespecified criteria. Mention of an abnormal
thought or behavior in the medical record was accepted as
evidence that it was observed by a caregiver. Lack of mention
of an abnormal thought or behavior was accepted as evidence
that it was not observed. Bivariate analyses were performed
to determine the differences between schizophrenic patients
with breast cancer and the general population using T-tests
for continuous variables and Chi‑square tests for categorical
variables.
Results
Patient criteria. During the time period studied, 126 patients
from 41 different VA facilities were identified by ICD-9-CM
codes as having been diagnosed with schizophrenia and subsequently with breast cancer. We received data on 122 patients
(97%); 67 patients were excluded following the chart review
as they did not have schizophrenia, did not have breast cancer,
had a history of breast cancer predating the diagnosis of schizophrenia, did not have initial breast cancer treatment during the
fiscal years 1999-2005, or had been deemed unsuitable for
adjuvant chemotherapy due to comorbid conditions other than
schizophrenia. The 55 remaining patients all had schizophrenia,
later developed breast cancer that appeared to be curable, and
were offered curative-intent treatment. All 55 patients appeared
to be candidates for adjuvant chemotherapy. They were deemed
evaluable and form the basis for this report.
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n

%

13
17
27
17
4
26
36
25
20
14
9
7

23
31
49
31
7
47
65
45
36
25
16
13

Thought blocking (self-interruption of speech before completion)
reflects disordered thought. Mention of the disordered thought in the
medical record was accepted as evidence that it had been observed
and was significant enough in the opinion of the caregiver to warrant mention. Lack of mention of the abnormal thought was taken as
evidence that it was not observed.
a

Patient characteristics and behaviors. Our patient population
comprised various ethnicities. Additionally, of the 44 patients
whose living conditions were recorded, over half were not
independent. Patients included were diagnosed with either
paranoid or other subtypes of schizophrenia.
Many patients exhibited behaviors characteristic of schizophrenia during chemotherapy sessions and surgery (Table II).
Classic evidence of disordered thought was often noted
(Table III). Details concerning hallucinations and delusions
were not recorded consistently; certain hospitals had recorded
them in detail and others appeared to have recorded only the
most notable incidents. For example, 5 of the 55 (9%) had homicidal ideation documented in the medical record; 17/55 (31%)
had documented suicidal ideation; and 12/55 patients (22%)
had previously attempted suicide. Ten of the 55 patients (18%)
had verbally abused ≥1 healthcare worker during ≥1 hospital
admission and 7 (13%) patients had physically assaulted ≥1
caregiver during ≥1 hospital admission.
Fourteen of the 35 (40%) patients for whom staging data
were available had TNM stages III-IV; at least 5 of these 14
(38%) patients had ignored obvious signs of breast cancer
(mass and/or ulceration noted by patient) for six months to
nine years; while 4 (29%) other patients with biopsy-proven
cancer had delayed treatment for >3 months. In the 25 patients
for whom the tumor size was recorded, 17 (68%) were >2 cm
(mean 5.8 cm).
Among the 55 patients who appeared to be candidates for
adjuvant cytotoxic therapy, there were 46 for whom adequate
data on this option were available; only 39/46 (85%) were
offered postoperative cytotoxic chemotherapy; 12 of these
39 (31%) patients refused or were non-compliant. Among
the 55 patients who appeared to be candidates for adjuvant
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endocrine therapy, there were 38 for whom adequate data on
this option were available. Only 25/38 (66%) were offered postoperative endocrine therapy and 8 of these 25 (32%) patients
refused or were non‑compliant. Refusal to take antipsychotic
medication was noted in the medical record of 25 of our 55
(45%) patients, but no statistically significant correlation was
observed between refusal to take antipsychotic medications and
refusal to accept adjuvant cytotoxic or endocrine chemotherapy
(Chi-square analysis). However, suicidal ideation, homicidal
ideation and a history of assaulting health care workers were
statistically significantly correlated with non-compliance with
adjuvant chemotherapy (p<0.05). History of substance abuse
was statistically significantly correlated with non-compliance
with endocrine therapy (p<0.05).
Discussion
Schizophrenia is a chronic, debilitating illness of unclear
etiology. The phenotype is diverse, complex and often frightening to the afflicted as well as their caregivers. Modern
genetic studies indicate that mutations in genes controlling
neurodevelopmental sequences are etiologic factors (14-18).
Environmental factors are also likely to be involved (16,17).
The anatomical, physiological and biochemical mechanisms
suggested by genetic data are penetrant in neural structures,
conform to what is known about the pathophysiology of
schizophrenia derived from non-genetic investigations, and
are concordant with the effects of these candidate genes (15).
Schizophrenia is estimated to account for 1.1% of the
disability-adjusted life‑years worldwide (8). The economic
burden of schizophrenia is estimated to be $30-40 billion in the
United States annually (19). It imposes a large burden on the
affected individual, family members and society. Individuals
with schizophrenia suffer appalling abuse throughout the
world when under care for a physical illness such as breast
cancer (20). Recent reports have documented widespread
‘neglect, abandonment, indignity, cruel and inhuman treatment, and punishment’ of schizophrenic subjects in spite of
relevant international law, recommendations from international organizations and statements from various commissions,
professional groups and government agencies (21).
Schizophrenia is fundamentally a psychotic disorder that
interferes with the understanding of disease processes and leads
to non-compliance with treatments. The majority of patients
have a paranoid component to their illness that further hinders
compliance with care. Decreased perception of pain and/or an
altered expression of the emotional response to pain are well
documented (22). Even in wealthy countries, those with major
mental illnesses have a mean life expectancy approximately
25 years shorter than the population as a whole. Suicide, homicide and similar causes account for approximately 40% of the
increased mortality rate although medical illnesses, including
myocardial infarction, cancer and infectious disease are also
estimated to play a role in this increased rate. Currently, available antipsychotic drugs reduce the mortality rate; however,
patients must ingest them to achieve this outcome (23). The
mortality rate due to breast cancer in schizophrenic patients is
significantly higher than that in the general population, as is
true for most types of cancer (24). The dimensions of this effect
in many common medical conditions have not been quantified.

Thus, there is limited awareness of strategies to provide good
clinical care for common physical disorders in these patients.
In 2006, there were an estimated 39.5 million hospitali
zations in the US, according to the Agency for Healthcare
Research and Quality (25). Approximately 1.4 million of
these hospitalizations were due to mental illness; 7.1 million
involved individuals with a mental illness in addition to the
physical problem which was the primary reason for hospitali
zation. Schizophrenia and other psychoses without physical
illness accounted for 381,000 hospital admissions. The cost
of treating mental illnesses in the US was estimated to be
$58 billion/year in 2006, making it one of the most costly
conditions (26).
A recent review of schizophrenia with answers to common
clinical questions has been published (9). Such patients often
have advanced-stage cancer at diagnosis, delay diagnosis,
refuse treatment, fail to comply with adjuvant chemotherapy
regimens and/or exhibit hostility to healthcare workers.
Patients with schizophrenia have quantifiable abnormalities
in their perception of pain and report pain differently than
patients without schizophrenia (22). Similar abnormalities in
other perceived sensations (including taste and smell) are also
known. The incorrect interpretation of other symptoms and
signs (presence of a breast mass, for example) appears to lead
to delays in seeking medical attention, delayed diagnosis and
suboptimal treatment.
In our subjects, certain presenting features, such as an
abnormal screening mammogram (present in 74% of our
patients), are similar to those in the general population of
breast cancer patients. However, our patients had high rates of
palpable breast mass (present in 80% of our patients), nipple
retraction (present in 30%) and nipple discharge (present in
11%) compared to non-schizophrenic subjects with breast
cancer, providing further evidence that schizophrenic patients
do not report symptoms as promptly as non-schizophrenic
ones. Signs of advanced breast cancer at diagnosis may be
related, in part, to the fact that many or most schizophrenic
patients see primary care doctors much less frequently than
they see psychiatrists, who focus on the control of the mental
illness rather than the diagnosis of physical diseases such as
cancer. The delay may be caused by patient factors (such as
confused thoughts, illicit drug abuse, altered perception of the
significance of evident breast lesions and abnormal perception of pain), physician factors (such as inattention to breast
symptoms, misdiagnosis and delay in consultation requests)
and/or societal factors (such as inadequate access to care or
insurance-related delays in treatment). Although the inability
to access healthcare is a significant reason for schizophrenic
patients not receiving the necessary treatment, all of the
patients included in this study were eligible for care in the
DVA system.
The majority (85%) of our patients received some type
of mastectomy rather than lumpectomy (15%). Mastectomy
carries a higher risk of complications than lumpectomy plus an
axillary procedure (27). Moreover, the procedure is contrary
to the current trend towards breast-conservation management.
Adverse events contributing to the markedly higher risk of
premature mortality are known to occur during hospitalization. In a large population-based study, Daumit et al estimated
that schizophrenic patients have more than a two-fold higher
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risk of several major complications during hospitalization
compared to those without schizophrenia (28). Complications
include nosocomial infections, decubitus ulcers, postoperative respiratory failure, deep venous thrombosis, sepsis and
hemorrhage. Such complications were observed in our patients
prior to adjuvant chemotherapy commencing and often delayed
diagnosis and treatment. These adverse events and the difficulties in receiving adjuvant systemic therapy presumably explain
the increased mortality rate observed in schizophrenic breast
cancer patients.
Our study revealed both a low rate of recommendation
of adjuvant chemotherapy by physicians and a low rate of
compliance by schizophrenic patients. There are numerous
mechanisms that lead schizophrenic breast cancer patients to
delay their care. For example, patients may believe that their
doctors intend to harm them and often do not trust the healthcare system. Some of the patients in our series believed that
‘cleansing teas’, meditation and other unorthodox therapies
were more likely to cure them than conventional methods.
Paranoia and delusions often led to violence directed towards
healthcare workers, as was observed in 10/55 (18%) of our
patients. We did not find a suitable published control group
for our study. In the general population, use of adjuvant endocrine therapy as part of a curative-intent treatment plan for
low-income breast cancer patients with medical insurance is
notably low. Only 64% of patients reported by Kimmick et al
had their prescriptions filled and the rate of adherence to the
adjuvant treatment plan was 60% (29). Women older than 65
with early‑stage, high-risk breast cancer (not selected for the
presence of schizophrenia but with medical insurance) also
frequently do not receive adjuvant chemotherapy (30).
There are, however, methodological limitations to our
study. Patients were identified by computer codes for diagnoses
of schizophrenia without the means to check whether these
patients fit the diagnostic criteria established by the American
Psychiatric Association. Another confounding factor that may
account for adverse outcomes of therapy for breast cancer is
the use of antipsychotic drugs, which may cause major complications, including obesity, diabetes, myocarditis, sedation,
agranulocytosis, anticholinergic effects, neuroleptic‑induced
movement disorders (including the life‑threatening neuroleptic malignant syndrome) and death (31). Our study is a
retrospective analysis of cases; thus, criteria for diagnoses
and reporting patterns for clinical features and treatment of
outcomes were presumably not recorded consistently among
our patients. In this report, we accepted the mention of a
symptom, sign or complication as evidence of its presence
unless stated otherwise. Similarly, we accepted absence of
the mention of a particular variable as evidence of its absence
unless stated otherwise.
Our study also has several strengths. To the best of our
knowledge, this is the largest series on this topic in the literature.
The DVA dataset from which the cases were selected is large,
with approximately 25 million registered veterans. Among
these, approximately five million receive care in DVA medical
centers each year. Most DVA subjects are male, unlike those
in most other databases. A comparison of female and male
breast cancer patients using the National Cancer Institute's
Surveillance, Epidemiology and End Results (SEER) data has
been published (32). Sharma et al recently reported the experi-
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ence of the Imperial College Healthcare NHS Trust, a large
British system based in London (33). Their aims and methods
differed somewhat from ours. These authors concluded that
schizophrenia does not affect the treatment of women with
breast cancer. They acknowledge that their conclusions are
not concordant with those of earlier reports. Our conclusions
also differ from those of Sharma et al. The reasons for this
discrepancy are speculative. The DVA system is enriched in
schizophrenic subjects since it is a safety net source of care
for poor veterans who are often homeless and/or unemployed.
In general, individuals with schizophrenia, as is the case with
individuals with other major mental illnesses, experience difficulty receiving indicated medical care (34). The patients in our
series had access to care in the DVA system, although they
may have had difficulty navigating it. Due to this difficulty, our
analysis is likely to have underestimated the effect of preexisting schizophrenia on the process of breast cancer treatment.
We strongly recommend that clinicians caring for schizophrenic patients with a significant intercurrent physical illness
such as breast cancer and known schizophrenia obtain a formal
psychiatric evaluation of the patient. There are several reasons
for obtaining such an evaluation. Having an independent
expert opinion from a psychiatrist is essential in determining
whether a patient is competent to make decisions about his/her
own medical care. The risk to caregivers and other patients
managing a schizophrenic patient is a matter of practical
concern that a psychiatrist is trained to assess. The available
evidence on this topic has been summarized by Friedman (35).
Violence in those with serious mental illness is a non-negligible
hazard even if the illness appears to be well controlled. The
hazard increases markedly when other predisposing factors
(particularly drug abuse) are present (36). The psychiatrist also
provides advice on the need for a minder to protect the patient
from self-harm. Even a short lapse in taking antipsychotic
medications markedly increases the risk of hospitalization in
schizophrenics (37). This is due to the recurrence of symptoms
of thought disorder. The authors believe that a psychiatrist
should be an integral part of the care team in such patients.
Our data show that patients with breast cancer and preexisting schizophrenia often present with late-stage cancer and
often do not understand their disease or the necessary treatment. These patients delay or refuse adjuvant chemotherapy
far more often than the population as a whole. They frequently
do not cooperate well with caregivers and may be better served
by radical surgery rather than breast-conserving treatment as
an initial therapy.
The effect of major mental illness on the diagnosis and
treatment of unrelated physical disease, as well as its effect
on the outcome of treatment, is grossly under-researched and
underreported. Further studies utilizing other data sets may
clarify the effects of major mental illness on the diagnosis,
treatment and course of unrelated physical disorders and
provide guidance to clinicians caring for such patients.
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